References
- Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev. 2016;68:3–12. doi:https://doi.org/10.1124/pr.114.009373.
- Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies. 2013;2:113–29. doi:https://doi.org/10.3390/antib2010113.
- Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review for Adcetris; Silver Spring (MD); 2011 [cited 2019 Dec 2]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000ClinPharmR.pdf.
- Kamath AV, Iyer S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res. 2015;32:3470–79. doi:https://doi.org/10.1007/s11095-014-1584-z.
- Kamath AV, Iyer S. Challenges and advances in the assessment of the disposition of antibody-drug conjugates. Biopharm Drug Dispos. 2016;37:66–74. doi:https://doi.org/10.1002/bdd.v37.2.
- Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30:184–89. doi:https://doi.org/10.1038/nbt.2108.
- Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 2014;16:994–1008. doi:https://doi.org/10.1208/s12248-014-9618-3.
- Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P. Bioanalysis of antibody-drug conjugates: American association of pharmaceutical scientists antibody-drug conjugate working group position paper. Bioanalysis. 2013;5:997–1006. doi:https://doi.org/10.4155/bio.13.38.
- Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis. 2013;5:201–26. doi:https://doi.org/10.4155/bio.12.299.
- Girish SR, Li C. Clinical pharmacology and assay consideration for characterizing pharmacokinetics and understanding efficacy and safety of antibody-drug conjugates. In: Gorovits B, Shord S, editors. Novel methods in bioanalysis and characterization of antibody-drug conjugates. London (UK): Future Medicine; 2015. p. 36–55.
- Advani RH, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, Hochberg E, Yalamanchili S, Kahn R, Lu D, et al. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2017;23:1167–76. doi:https://doi.org/10.1158/1078-0432.CCR-16-0772.
- Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16:704–15. doi:https://doi.org/10.1016/S1470-2045(15)70128-2.
- Infante JR, Sandhu SK, McNeil CM, Kabbarah O, Li C, Zhong W, Asundi J, Hamid O. A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma. AACR Annual Meeting; 2014; San Diego, CA.
- Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, et al. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther. 2016;15:439–47. doi:https://doi.org/10.1158/1535-7163.MCT-15-0693.
- Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016;27:2124–30. doi:https://doi.org/10.1093/annonc/mdw401.
- Burris HA, Gordon MS, Gerber DE, Spigel DR, Mendelson DS, Schiller JH, Wang Y, Choi Y, Kahn RS, Wood K, et al. A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC). ASCO. 2014 https://meetinglibraryascoorg/record/91851/abstract.
- Sukumaran S, Zhang C, Leipold DD, Saad OM, Xu K, Gadkar K, Samineni D, Wang B, Milojic-Blair M, Carrasco-Triguero M, et al. Development and translational application of an integrated, mechanistic model of antibody-drug conjugate pharmacokinetics. AAPS J. 2017;19:130–40. doi:https://doi.org/10.1208/s12248-016-9993-z.
- Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J. 2019;9:17. doi:https://doi.org/10.1038/s41408-019-0178-8.
- Samineni D, Kagedal M, Gillespie B, Fine B, Lu D, Choi YJ, Li C, Jin JY, Girish S. Time-to-event modeling of peripheral neuropathy – platform mega-analysis of eight vc-MMAE antibody-drug conjugates (ADCs). AAPS National Biotechnology Conference (NBC); 2016; Boston, MA.
- Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;29:2354–66. doi:https://doi.org/10.1007/s11095-012-0800-y.
- Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3:61–66. doi:https://doi.org/10.4161/mabs.3.1.13799.
- Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–59. doi:https://doi.org/10.2165/11535960-000000000-00000.
- Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733–35. doi:https://doi.org/10.1038/nbt.3212.
- Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013;53:866–77. doi:https://doi.org/10.1002/jcph.116.
- Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5ʹ-upstream regulatory region. Biochem Biophys Res Commun. 1999;259:201–05. doi:https://doi.org/10.1006/bbrc.1999.0752.